Insilico Medicine (HKEX: 3696) and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced a multi-target strategic alliance pairing Insilico’s AI drug discovery platform with Bora’s global development, manufacturing, and commercialization infrastructure, with the companies disclosing a potential collaboration value exceeding USD 2.5 billion, contingent on future agreements and achievement of development milestones. The deal extends Insilico’s platform strategy beyond discovery into manufacturing and commercial execution.
Insilico’s contribution to the alliance is its Pharma.AI platform, which spans three functional modules: target identification, generative chemistry for de novo molecular design, and multi-parameter molecule optimization covering potency, selectivity, and ADMET properties. The platform has generated 31 preclinical candidates since 2021, 13 of which have received IND approval or clearance. Its most independently validated asset is ISM018_055, an AI-generated TNIK inhibitor for idiopathic pulmonary fibrosis that reached Phase II clinical evaluation.
Bora has expanded rapidly through acquisitions to become one of Asia’s largest publicly listed CDMOs, with manufacturing operations spanning Taiwan, North America, and other international markets. The firm will contribute is its end-to-end services infrastructure operating under a dual CDMO and commercial model, encompassing formulation, chemistry, manufacturing and controls, regulatory development, scale-up, quality systems, and supply chain execution. The alliance also contemplates applying Insilico’s AI capabilities to Bora’s internal operations, including manufacturing efficiency, supply chain, and workforce AI literacy — an operational scope that goes beyond standard drug discovery partnerships.